Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Loncar Cancer Immunotherapy ETF (CNCR)

Loncar Cancer Immunotherapy ETF (CNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Exchange Traded Concepts
  • Assets Under Management 33,948,800
  • Market Capitalization, $K 33,949
  • Shares Outstanding, K 1,650
  • 60-Month Beta 1.72
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 0.35 (1.69%)
  • Most Recent Dividend 0.350 on 12/28/17
  • Management Fee 0.79%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.13 +14.07%
on 10/15/19
20.84 -0.77%
on 11/12/19
+2.33 (+12.70%)
since 10/11/19
3-Month
17.82 +16.05%
on 10/02/19
20.84 -0.77%
on 11/12/19
+1.00 (+5.06%)
since 08/12/19
52-Week
16.87 +22.59%
on 12/24/18
22.53 -8.21%
on 02/25/19
+0.10 (+0.49%)
since 11/12/18

Most Recent Stories

More News
Cancer-Fighting Stocks & ETF: What You Need to Know

Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

BMY : 58.39 (+0.41%)
MRK : 84.12 (+1.01%)
AZN : 47.08 (+0.43%)
CNCR : 20.68 (+0.58%)
CHNA : 24.59 (-1.80%)
NKTR : 20.34 (-3.05%)
IOVA : 22.90 (-4.06%)
Why Cancer-Fighting Stocks & ETFs Are Soaring

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

LLY : 113.17 (+0.33%)
AZN : 47.08 (+0.43%)
BMY : 58.39 (+0.41%)
MRK : 84.12 (+1.01%)
CNCR : 20.68 (+0.58%)
CELG : 110.00 (+0.39%)
MRTX : 104.33 (+1.11%)
NKTR : 20.34 (-3.05%)
IOVA : 22.90 (-4.06%)
CHNA : 24.59 (-1.80%)
Trump Proposes 2020 Budget: ETFs to Top & Flop

Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.

QCLN : 22.65 (+0.35%)
ITA : 229.59 (+0.18%)
BTEC : 33.86 (+0.73%)
CNCR : 20.68 (+0.58%)
XLP : 60.87 (+0.33%)
GNRX : 22.42 (-0.06%)
BBC : 27.49 (-0.51%)
EWW : 43.99 (-2.20%)
PBW : 30.60 (+0.62%)
XAR : 110.61 (+0.38%)
MOO : 67.22 (+0.13%)
CARZ : 34.82 (-0.09%)
PPA : 69.27 (+0.30%)
IEIH : 26.21 (+0.38%)
Trump Proposes 2020 Budget: ETFs to Top & Flop

Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.

QCLN : 22.65 (+0.35%)
ITA : 229.59 (+0.18%)
BTEC : 33.86 (+0.73%)
CNCR : 20.68 (+0.58%)
XLP : 60.87 (+0.33%)
GNRX : 22.42 (-0.06%)
BBC : 27.49 (-0.51%)
EWW : 43.99 (-2.20%)
PBW : 30.60 (+0.62%)
XAR : 110.61 (+0.38%)
MOO : 67.22 (+0.13%)
CARZ : 34.82 (-0.09%)
PPA : 69.27 (+0.30%)
IEIH : 26.21 (+0.38%)
Best and Worst ETFs of Last Week

After a solid comeback, the momentum on the Wall Street cooled down last week given the round of dismal data across the globe, the European Central Bank's surprise move and dismal U.S. jobs data that renewed...

XES : 6.97 (-1.83%)
SCIN : 13.77 (-0.07%)
CNCR : 20.68 (+0.58%)
DWSH : 24.39 (+0.23%)
BDRY : 16.98 (+2.60%)
VXXB : 26.65 (+3.78%)
Best and Worst ETFs of Last Week

After a solid comeback, the momentum on the Wall Street cooled down last week given the round of dismal data across the globe, the European Central Bank's surprise move and dismal U.S. jobs data that renewed...

XES : 6.97 (-1.83%)
SCIN : 13.77 (-0.07%)
CNCR : 20.68 (+0.58%)
DWSH : 24.39 (+0.23%)
BDRY : 16.98 (+2.60%)
VXXB : 26.65 (+3.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade CNCR with:

Fund Summary

The Loncar Cancer Immunotherapy ETF seeks investment results that correspond generally to the price and yield per for mance, before fees and expenses, of the Loncar Cancer Immunotherapy Index.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

2nd Resistance Point 20.99
1st Resistance Point 20.84
Last Price 20.68
1st Support Level 20.53
2nd Support Level 20.39

See More

52-Week High 22.53
Last Price 20.68
Fibonacci 61.8% 20.37
Fibonacci 50% 19.70
Fibonacci 38.2% 19.03
52-Week Low 16.87

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar